phenyl aminosalicylate
Trade name: pheny-pas-tebamin
Small moleculeapproved
Phenyl Aminosalicylate is the phenyl ester of para-aminosalicylic acid, reported to have less side effects than simple salts of para-aminosalicylic acid. It’s a second-line antituberculosis drug with a high incidence of hypersensitivity reactions and gastrointestinal upset. — NCATS
Clinical trial activity
0 trials · 0 clinical orgs · 2 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Timeline
1950s
- Jun 1, 1959
Purdue Pharmaceuticals — First NDA Organization
- Jun 1, 1959
Purdue Pharmaceuticals — NDA Organization
Indications
Approved for
Mechanism of action
- Unspecified targetOTHER
Unknown
Approval history
- approved—
Chemistry & pharmacology
Loading structure…
SMILES
NC1=CC=C(C(=O)OC2=CC=CC=C2)C(O)=C1- Mol. weight
- 229.2313 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Discontinued
Oral
Yes
Parenteral
No
Topical
No
Sources
- NCATS52936SIP7V ↗
- ChEMBLCHEMBL1200868 ↗
Also known as
- fenamisal
- fenamisal
- fenamisal
- fenamisal
- fenamisal
- p-aminosalicylic acid phenyl ester
- phenyl aminosalicylate
- phenyl aminosalicylate
- phenyl aminosalicylate
- phenyl aminosalicylate
- phenyl aminosalicylate
- phenyl p-aminosalicylate
- pheny-pas-tebamin
- pheny-pas-tebamin
- tebamin
- tebanyl
Organizations
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Pharmaceutical Research Associates, Inc. (PRA) | For profit | NDA2 | — |
| Purdue Pharmaceuticals | For profit | NDA | Jun 1, 1959 |